Treatment with MAVENCLAD must be initiated and supervised by a physician experienced in the treatment of MS.
Posology: The recommended cumulative dose of MAVENCLAD is 3.5 mg/kg body weight over 2 years, administered as 1 treatment course of 1.75 mg/kg per year. Each treatment course consists of 2 treatment weeks, one at the beginning of the first month and one at the beginning of the second month of the respective treatment year. Each treatment week consists of 4 or 5 days on which a patient receives 10 mg or 20 mg (one or two tablets) as a single daily dose, depending on body weight. For details, see Tables 2 and 3 as follows.
Following completion of the 2 treatment courses, no further cladribine treatment is required in years 3 and 4 (see Pharmacology: Pharmacodynamics under Actions). Re-initiation of therapy after year 4 has not been studied.
Criteria for initiating and continuing therapy: Lymphocyte counts must be: normal before initiating MAVENCLAD in year 1, at least 800 cells/mm3 before initiating MAVENCLAD in year 2.
If necessary, the treatment course in year 2 can be delayed for up to 6 months to allow for recovery of lymphocytes. If this recovery takes more than 6 months, the patient should not receive MAVENCLAD anymore.
Distribution of dose: The distribution of the total dose over the 2 years of treatment is provided in Table 2. For some weight ranges the number of tablets may vary from one treatment week to the next. Use of oral cladribine in patients weighing less than 40 kg has not been investigated. (See Table 2.)
Click on icon to see table/diagram/image
Table 3 shows how the total number of tablets per treatment week is distributed over the individual days. It is recommended that the daily cladribine doses in each treatment week be taken at intervals of 24 hours at approximately the same time each day. If a daily dose consists of two tablets, both tablets are taken together as a single dose. (See Table 3.)
Click on icon to see table/diagram/image
A missed dose must be taken as soon as remembered on the same day according to the treatment schedule.
A missed dose must not be taken together with the next scheduled dose on the following day. In the case of a missed dose, the patient must take the missed dose on the following day, and extend the number of days in that treatment week. If two consecutive doses are missed, the same rule applies, and the number of days in the treatment week is extended by two days.
Concomitant use of other oral medicinal products: It is recommended that administration of any other oral medicinal product be separated from that of MAVENCLAD by at least 3 hours during the limited number of days of cladribine administration (see Interactions).
Special populations: Renal impairment: No dedicated studies have been conducted in patients with renal impairment.
In patients with mild renal impairment (creatinine clearance 60 to 89 mL/min), no dosage adjustment is considered necessary (see Pharmacology: Pharmacokinetics under Actions).
Safety and efficacy in patients with moderate or severe renal impairment have not been established.
Therefore, MAVENCLAD is contraindicated in these patients (see Contraindications).
Hepatic impairment: No studies have been conducted in patients with hepatic impairment.
Although the importance of hepatic function for the elimination of cladribine is considered negligible (see Pharmacology: Pharmacokinetics under Actions), in the absence of data, use of MAVENCLAD is not recommended in patients with moderate or severe hepatic impairment (Child-Pugh score >6).
Elderly: Clinical studies with oral cladribine in MS did not include patients over 65 years of age; therefore, it is not known whether they respond differently from younger patients.
Caution is recommended when MAVENCLAD is used in elderly patients, taking into account the potential greater frequency of decreased hepatic or renal function, concomitant diseases and other medicinal therapies.
Paediatric population: The safety and efficacy of MAVENCLAD in patients below the age of 18 years have not been established. No data are available.
Method of administration: MAVENCLAD is for oral use. The tablets must be taken with water, and swallowed without chewing. The tablets can be taken independent of food intake.
As the tablets are uncoated, they must be swallowed immediately once removed from the blister and not be left exposed on surfaces or handled for any period of time greater than that required for dosing. If a tablet is left on a surface, or if a broken or fragmented tablet is released from the blister, the area must be thoroughly washed.
The patient's hands must be dry when handling the tablets and washed thoroughly afterwards.